Nephrotoxicity in cancer treatment: An overview

doi:10.5306/wjco.v11.i4.190

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (18291)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

1507

WORD

227

HTML

13945

Figures (1-3)

465

Tables (1-1)

228

Sum=16372

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

772

Download

1147

Sum=1919

Apr 24, 2020 (publication date) through Apr 19, 2024

Times Cited of This Article

Times Cited (61)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Oncol. Apr 24, 2020; 11(4): 190-204
Published online Apr 24, 2020. doi: 10.5306/wjco.v11.i4.190

Full Size Figure Download Figure

Figure 3 Chemotherapy-induced nephron specific segment injury. TKI: Tyrosine kinase inhibitors; VEGF: Vascular endothelial growth factor; IL-2: Interleukin-2; INF-a: Interferon-alpha.

Citation: Santos MLC, Brito BB, da Silva FAF, Botelho ACDS, Melo FF. Nephrotoxicity in cancer treatment: An overview. World J Clin Oncol 2020; 11(4): 190-204
URL: https://www.wjgnet.com/2218-4333/full/v11/i4/190.htm
DOI: https://dx.doi.org/10.5306/wjco.v11.i4.190